-Parties: The applicant was Salix Pharmaceuticals Inc. The respondent was Apotex Inc.

-Subject Matter: This is a Federal Court action under section 6 of the Patented Medicines (Notice of Compliance) Regulations, commenced by Salix Pharmaceuticals Inc. in response to a Notice of Allegation served by Apotex Inc. regarding its proposed APO-RIFAXIMIN product. Salix seeks declaratory and injunctive relief on the basis that Apotex's product would infringe Canadian Patent No. 2,739,436. The case is ongoing.

-Date: The hearing was set on July 9, 2026.

-Venue: This was a federal case before the Federal Court.

-Amount: No financial award was specified.